Mark Hofer Esq. Joins PsychoGenics as General Counsel.
Prior to joining the Brown Rudnick Berlack & Israels, Mr. Hofer served as Senior Vice President, General Counsel and then Chief Patent Counsel for Genzyme Corporation. Previous to that he was Chief Patent Counsel for Integrated Genetics and Patent Counsel for Johnson & Johnson. He has a bachelor's degree in Biology/Microbiology, a master's degree in Biomedical Engineering and a doctorate in Jurisprudence. He has published and lectured extensively on various intellectual property issues before many organizations and law schools, including the Harvard Law School, in the United States and Europe.
"Mark has extensive experience with biotechnology and pharmaceutical companies. He has devoted much of his work to assisting clients to identify and implement strategies for optimizing market opportunities within the context of a complex patent environment," said Emer Leahy, Ph.D., President and CEO. "We are very fortunate to have Mark on our team. He is a very creative thinker with a track record of outstanding contribution to the companies he represents. Here at PsychoGenics, Mark will play a leading role in business and patent development activities."
PsychoGenics, a private biopharmaceutical company, with expertise in the field of behavioral neurobiology, and provider CNS drug discovery solutions to Pharmaceutical and Biotechnology companies, is combining its expertise in behavioral neurobiology with the power of bioinformatics to develop a breakthrough, in vivo preclinical behavioral testing platform. This automated and computerized high-throughput platform offers companies an alternative approach to target discovery and validation, and drug discovery by providing faster, more objective and higher quality results than traditional, subjective manual approaches.
MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X63111285
Contact: Bill Fasnacht, CFO - COO of PsychoGenics Inc., +1-914-593-0640, ext. 3003, firstname.lastname@example.org